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On page 1129, the n values in the table column headings were incorrect.

The corrected Table 1 is shown below:Table 1Patient Characteristics in the SUMMIT Study Population, the Biomarker Substudy Population, and Split by Cardiac Troponin I QuintileTroponin Quintile 1 (\<2.3 ng/l) (n = 307)Troponin Quintile 2 (≥2.3 to \<3.4 ng/l) (n = 325)Troponin Quintile 3 (≥3.4 to \<4.8 ng/l) (n = 319)Troponin Quintile 4 (≥4.8 to \<7.7 ng/l) (n = 330)Troponin Quintile 5 (≥7.7 ng/l) (n = 318)Biomarker Substudy[∗](#tbl1fnlowast){ref-type="table-fn"} (n = 1,673)SUMMIT ITT-E Population (n = 16,485)Median troponin1.72.84.05.812.04.0-Age, yrs63 ± 865 ± 867 ± 868 ± 768 ± 766 ± 865 ± 8Female172 (56)153 (47)107 (34)98 (30)80 (25)635 (38)4,196 (25)BMI, kg/m^2^30 ± 631 ± 731 ± 631 ± 731 ± 731 ± 728 ± 6Systolic blood pressure, mm Hg128 ± 14129 ± 16132 ± 16131 ± 16134 ± 19131 ± 16135 ± 15Heart rate, beats/min75 ± 1074 ± 1173 ± 1173 ± 1173 ± 1173 ± 1176 ± 10Estimated GFR, ml/min/1.73 m^2^101.2 ± 33.6100.5 ± 37.1100.5 ± 38.495.2 ± 36.189.3 ± 34.997.7 ± 36.797.3 ± 36.6CRP, mg/l5.3 ± 6.96.5 ± 8.35.6 ± 7.06.5 ± 10.36.8 ± 8.76.2 ± 8.36.2 ± 8.3Past medical history Prior myocardial infarction or coronary revascularization71 (23)89 (27)112 (35)145 (44)162 (51)601 (36)3,436 (21) Coronary artery disease113 (37)132 (41)148 (46)186 (56)199 (63)818 (49)8,379 (51) Congestive heart failure15 (5)11 (3)21 (7)34 (10)61 (19)146 (9)3,456 (21) Hypercholesterolemia243 (79)280 (86)283 (89)295 (89)292 (92)1458 (87)11,518 (70) Hypertension258 (84)285 (88)300 (94)307 (93)302 (95)1519 (91)14,851 (90) Diabetes mellitus108 (35)116 (36)116 (36)138 (42)140 (44)642 (38)4,997 (30) Family history of CVD128 (42)128 (39)116 (36)146 (44)145 (46)691 (41)3,429 (21)Respiratory history Former smoker141 (46)152 (47)170 (53)178 (54)169 (53)845 (51)8,807 (53) Post-bronchodilator FEV~1~, l1.7 ± 0.41.7 ± 0.41.7 ± 0.41.7 ± 0.41.7 ± 0.41.7 ± 0.41.7 ± 0.4 Predicted post-bronchodilator FEV~1~, % of predicted59.7 ± 6.959.4 ± 6.759.2 ± 6.959.5 ± 6.659.3 ± 7.059.4 ± 6.859.7 ± 6.1Exacerbations in 12 months before study 0220 (72)233 (72)228 (71)249 (75)236 (74)1,215 (73)10,021 (61) 155 (18)57 (18)58 (18)47 (14)55 (17)290 (17)4,020 (24) 2+32 (10)35 (11)33 (10)34 (10)27 (8)168 (10)2,444 (15)Concomitant cardiovascular therapy Antiplatelet therapy176 (57)196 (60)197 (62)231 (70)238 (75)1,081 (65)8,517 (52) Statin therapy207 (67)251 (77)238 (75)269 (82)245 (77)1,263 (75)10,721 (65) Antiplatelet and statin therapy137 (45)167 (51)157 (49)198 (60)191 (60)886 (53)6151 (37)Treatment allocation Placebo83 (27)87 (27)81 (25)78 (24)92 (29)439 (26)4,111 (25) Fluticasone furoate69 (22)87 (27)83 (26)76 (23)74 (23)415 (25)4,135 (25) Vilanterol87 (28)84 (26)70 (22)80 (24)77 (24)416 (25)4,118 (25) Combination therapy68 (22)67 (21)85 (27)96 (29)75 (24)403 (24)4,121 (25)[^1][^2][^3]

The authors apologize for these errors.

The online version of the article has been corrected to reflect these changes.

[^1]: Values are mean ± SD or n (%).

[^2]: BMI = body mass index; CVD = cardiovascular disease; FEV~1~ = forced expiratory volume in 1 s; GFR = glomerular filtration rate; ITT-E = intention-to-treat efficacy.

[^3]: Of the 1,673 patients in the biomarker population, 74 did not have baseline cardiac troponin I measured and are therefore not included in the cardiac troponin I quintiles and analyses.
